Handelsbanken Fonder AB Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Handelsbanken Fonder AB grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,049 shares of the biopharmaceutical company’s stock after purchasing an additional 12,547 shares during the period. Handelsbanken Fonder AB owned about 0.06% of Regeneron Pharmaceuticals worth $35,451,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $226,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 32.7% during the second quarter. Oppenheimer Asset Management Inc. now owns 2,608 shares of the biopharmaceutical company’s stock valued at $1,369,000 after purchasing an additional 643 shares during the last quarter. Flagship Harbor Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $467,000. Finally, World Investment Advisors increased its holdings in shares of Regeneron Pharmaceuticals by 51.7% during the second quarter. World Investment Advisors now owns 549 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 187 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. HSBC raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Oppenheimer reiterated an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Zacks Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Wells Fargo & Company lifted their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Finally, UBS Group boosted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $793.81.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Hedge funds and investment sites are highlighting REGN as a top gene-therapy / biotech buy, noting the company’s late-stage pipeline and recent regulatory wins (including a Feb. 24 FDA action referenced in the coverage). Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: Regulatory news: the EMA has recommended Dupixent for EU approval to treat chronic spontaneous urticaria (CSU) in children aged 2–11 — if approved this would be a first-in-class targeted option for that age group and should expand addressable market for Dupixent in Europe. Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
• Positive Sentiment: Analyst momentum: Wall Street Zen (via media coverage) upgraded REGN to a Buy, reflecting bullish analyst sentiment that can support further upside and investor confidence. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Wall Street Zen
• Positive Sentiment: Product strength: coverage (Seeking Alpha) emphasizes that Dupixent continues to drive strong sales growth (reported ~22.8% YoY in Q4) and remains central to Regeneron’s long-term revenue outlook. Why Dupixent Keeps Regeneron A Top Big Pharma Pick
• Neutral Sentiment: Relative performance: a recent note asks whether REGN has underperformed the Nasdaq over the past year — a reminder that, despite bullish fundamentals, the stock has lagged broad-market gains and could face rotation risk. Analysts remain largely positive, however. Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock valued at $4,142,738 in the last ninety days. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

REGN opened at $781.67 on Friday. The business has a fifty day moving average of $771.59 and a 200 day moving average of $680.78. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a market cap of $82.64 billion, a P/E ratio of 18.81, a PEG ratio of 2.07 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the business posted $12.07 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.